An interventional study of Green Light stimulation and Equal Energy White stimulation in Chronic Low-back Pain, Chronic Pain and Fibromyalgia, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Chronic Pain by University of North Carolina, Chapel Hill — 3 open to participants now, 3 under way, none of them phase 3. Chronic Pain · University of North Carolina, Chapel Hill.
Among the 12 studies in Chronic Pain by University of North Carolina, Chapel Hill, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 9th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →3 of the 12 studies in Chronic Pain by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
University of North Carolina, Chapel Hill
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 30 across the 11 interventional studies, 36 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
2 of the studies in Chronic Pain by University of North Carolina, Chapel Hill that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06228755University of North Carolina, Chapel HillMAGIC Study: More Access to Group Integrative Care | 2027-06 |
| NCT05956067University of North Carolina, Chapel HillChromatic Retinal Stimulation to Reduce Chronic Pain and Pain Sensitivity | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Chronic Pain by University of North Carolina, Chapel Hill, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Participants with chronic pain conditions including chronic low back pain and fibromyalgia may benefit from light stimuli presented to the retina to reduce chronic pain severity and pain sensitivity. Participants will be recruited into this study and will be presented with one of three uniform light stimuli via a wide-field ganzfeld in three conditions to determine the retinal mechanisms that reduce pain. This work will lead to a greater understanding of retinal mechanisms that contribute to pain and will assist the design of future studies to harness the potential of light based pain therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Equal energy white light at 500 lux. The International Commission on Illumination (CIE) coordinates of this light are (x=y=0.33), indicating that the stimulus appears uniformly white which means that the activation of each of the three classes of photoreceptors are equivalent, thus silencing any chromatic opponency. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
Device: Equal Energy White stimulation
Green light at 500 lux. Participants will view 545 nm green light delivered via a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
Device: Green Light stimulation
The S-cone modulating light stimulus will alternate between two light conditions at 500 lux that will activate the S-cones by about 100x differentially between the two conditions while maintaining the L- an M-cones at constant activation between the two alternating conditions using 427 nm versus 545 nm light. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
Device: S-cone modulating white light
A portable battery-operated ganzfeld light display will be used to deliver green light for 2 hours per day for 5 consecutive days.
A portable battery-operated ganzfeld light display will be used to deliver white light for 2 hours per day for 5 consecutive days.
A portable battery-operated ganzfeld light display will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
Feasibility: Percent follow-up
Percent follow-up for 1 week baseline visit. Follow-up greater than 70% will be considered feasible.
Time frame: 1 week
Feasibility: Percent of flash surveys completed
Percent of flash surveys completed during light stimulation period. 0% is the lowest and 100% is the highest. Higher percentages indicate greater percent of flash surveys completed.
Time frame: 1 week
Feasibility: Self-reported light stimulation sessions completed
Self-reported light stimulation sessions completed by flash survey administered after each light stimulation session over the 5 day stimulation period. Number of sessions will be reported the minimum is 0 and the maximum is 5.
Time frame: 1 week
Change in pain intensity after stimulation
Pain intensity measured by a 0-10 numeric rating scale for overall pain. 0 represents no pain, and 10 represents the worst pain imaginable.
Time frame: Baseline, 1 week
Change in pressure pain threshold
Pressure Pain Threshold is the threshold in which pain is experienced in response to increasing force applied to the trapezius measured by a pressure algometer in kilograms of force per square centimeter (kgf/cm\^2). The higher the value, the higher the threshold. The maximum is 10 kgf/cm\^2 and minimum is 0.
Time frame: Baseline, 1 week
Change in Conditioned Pain modulation
Conditioned Pain modulation magnitude will be calculated as the difference in mean pressure pain threshold (kgf/cm\^2) measured prior to and during the conditioning stimulus (cold water bath), with increases in pressure pain threshold during conditioning interpreted as evidence of efficient endogenous pain inhibition.
Time frame: Baseline, 1 week
Change in Temporal Summation
Temporal Summation. The investigators will evaluate temporal summation using a 40g Neuropen applied to the skin of the volar forearm and lumbar region, following a train of 10 identical stimuli (1 Hz). Participants will report retrospectively, the pain intensity of the 1st and 10th pinprick using a 0-10 numerical rating scale (NRS). 0 is the minimum and 10 is the maximum pain intensity that will be reported.
Time frame: Baseline, 1 week
Change in activity measured with an accelerometer
Activity will be measured by an accelerometer. Average daily step count for the duration of the stimulus. Average non-sedentary time in minutes will able be determined over the stimulation period and compared to the data collected over the 1 week run-in period.
Time frame: 1 week prior to baseline and 1 week during light stimulation
Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 18 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available 1 year after completion of the study and will be available for an additional 2 years.
Access criteria: Data use agreement with University before deidentified information requested will be shared.
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Oct 2027, 49 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 49 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jul 2026 → Oct 2027 and completion Jul 2026 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →